Key result
Dynapenic and sarcopenic obesity linked to higher CVD risk factors in peritoneal dialysis patients.
Why the study?
Dynapenic obesity and sarcopenic obesity increase CVD and mortality in nonuremic patients, but their prevalence and associations with CVD risk factors in peritoneal dialysis patients were undetermined.
What is the prevalence of dynapenic obesity and sarcopenic obesity and their association with CVD risk factors in peritoneal dialysis patients?
Cross-Sectional
Yes
What is the prevalence of dynapenic obesity and sarcopenic obesity and their association with CVD risk factors in peritoneal dialysis patients?
Dynapenic obesity and sarcopenic obesity, though relatively uncommon in peritoneal dialysis patients, are associated with increased cardiovascular risk factors such as inflammation and dyslipidemia.
Associations in PD patients are hypothesis-generating; leaves open whether dynapenic or sarcopenic obesity independently predict CVD outcomes.
BACKGROUND: Dynapenic obesity and sarcopenic obesity increase cardiovascular disease (CVD) and mortality in nonuremic patients. The present study was designed to determine the prevalence of dynapenic obesity and sarcopenic obesity and their associations with CVD risk factors in peritoneal dialysis (PD) patients. METHODS: All eligible PD patients in Tehran peritoneal dialysis centers were included in this cross-sectional study. Skeletal muscle mass and fat mass were assessed using bioelectrical impedance analysis. Muscle strength and physical performance were determined using hand grip strength and a 4-meter walk gait speed test, respectively. In addition, a 5-mL blood sample was obtained from each patient. RESULTS: The prevalence of dynapenic obesity and sarcopenic obesity were 11.4% and 3.8% in PD patients, respectively. Serum high-sensitive C-reactive protein (hs-CRP), soluble intercellular adhesion molecule type 1, triglyceride, total cholesterol, and low-density lipoprotein cholesterol were significantly higher in PD patients with dynapenic obesity than in dynapenic nonobese and nondynapenic nonobese patients. Similarly, serum concentrations of CVD risk factors in PD patients with sarcopenic obesity were higher than in nonsarcopenic nonobese patients, but these differences were statistically significant only for serum hs-CRP and triglyceride. In addition, muscle strength and skeletal muscle mass percentage were negatively associated with markers of inflammation and dyslipidemia, whereas body fat percentage was positively associated with these CVD risk factors. CONCLUSION: This study indicates that although the prevalence of dynapenic obesity and sarcopenic obesity are relatively low in PD patients, these disorders may be associated with CVD risk factors.
No takes yet. Share an insight, caveat, or question.
Tabibi et al. (2018) conducted a cross-sectional in Peritoneal dialysis. Dynapenic obesity and sarcopenic obesity vs. Nonobese and nondynapenic/nonsarcopenic patients was evaluated on Prevalence of dynapenic and sarcopenic obesity and their associations with CVD risk factors. Dynapenic obesity (11.4%) and sarcopenic obesity (3.8%) in peritoneal dialysis patients were associated with significantly higher levels of cardiovascular disease risk factors such as hs-CRP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: